Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H24O2 |
| Molecular Weight | 272.3826 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@]12CC[C@]3([H])c4ccc(cc4CC[C@@]3([H])[C@]2([H])CC[C@]1([H])O)O
InChI
InChIKey=VOXZDWNPVJITMN-ZBRFXRBCSA-N
InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1
| Molecular Formula | C18H24O2 |
| Molecular Weight | 272.3826 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00783https://pubchem.ncbi.nlm.nih.gov/compound/222757https://www.ncbi.nlm.nih.gov/pubmed/11250930Curator's Comment:: description was created based on several sources, including
https://books.google.ru/books?id=68n6f1Nw6EEC&pg=PA64&redir_esc=y#v=onepage&q&f=false | https://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm116143.pdf | https://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM338208.pdf
Sources: http://www.drugbank.ca/drugs/DB00783https://pubchem.ncbi.nlm.nih.gov/compound/222757https://www.ncbi.nlm.nih.gov/pubmed/11250930
Curator's Comment:: description was created based on several sources, including
https://books.google.ru/books?id=68n6f1Nw6EEC&pg=PA64&redir_esc=y#v=onepage&q&f=false | https://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm116143.pdf | https://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM338208.pdf
Estradiol 3-sulfate or 17beta-estradiol 3-sulfate is a biologically inactive metabolite of estradiol, which can be converted by steryl sulfatase again to the parent estrogen.
CNS Activity
Sources: https://books.google.ru/books?id=L4YQ50SbBnsC&pg=PA223&lpg=PA223&dq=estradiol+cross+blood+brain+barrier&source=bl&ots=1XAPNkXVXI&sig=_VCp7qIuyiwBe9cGGJDMvmdR8zg&hl=ru&sa=X&ved=0ahUKEwjjk6vD8r7PAhWCFywKHU3xD8c4ChDoAQg4MAU#v=onepage&q=estradiol%20cross%20blood%20brain%20barrier&f=false, retrieved fromhttps://www.ncbi.nlm.nih.gov/pubmed/25231731
Curator's Comment:: Known to be CNS active in rats. Human data not available.
Originator
Sources: https://books.google.ru/books?id=_J2ti4EkYpkC&pg=PA1478&lpg=PA1478&dq=ESTRADIOL+year+introduced&source=bl&ots=N5lzH8ALwu&sig=V9zqvrxhsCojxBpoWmAWSN7AXcc&hl=ru&sa=X&ved=0ahUKEwj975678L7PAhVGXSwKHb5cBkUQ6AEISDAH#v=onepage&q=ESTRADIOL%20year%20introduced&f=false, retrieved from Pharmaceutical Manufacturing Encyclopedia, 3rd Edition : William Andrew Publishing, p.1475
Curator's Comment:: Also in Ravina E., Kubinyi H. (2011). The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. John Wiley & Sons. p. 175.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P08842 Gene ID: 412.0 Gene Symbol: STS Target Organism: Homo sapiens (Human) |
|||
Target ID: CHEMBL206 Sources: http://www.drugbank.ca/drugs/DB00783 |
0.0084 nM [EC50] | ||
Target ID: CHEMBL242 Sources: http://www.drugbank.ca/drugs/DB00783 |
1.4 nM [EC50] | ||
Target ID: CHEMBL1871 |
19.1 nM [IC50] | ||
Target ID: CHEMBL206 |
0.13 nM [Ki] | ||
Target ID: CHEMBL242 |
0.09 nM [Kd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | CLIMARA Approved UseClimara is an estrogen indicated for:
•Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause
•Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause
•Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure
•Prevention of Postmenopausal Osteoporosis Launch Date1.57679993E11 |
|||
| Preventing | CLIMARA Approved UseClimara is an estrogen indicated for:
•Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause
•Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause
•Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure
•Prevention of Postmenopausal Osteoporosis Launch Date1.57679993E11 |
|||
| Primary | CLIMARA Approved UseClimara is an estrogen indicated for:
•Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause
•Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause
•Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure
•Prevention of Postmenopausal Osteoporosis Launch Date1.57679993E11 |
|||
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14.7 pg/mL |
0.25 mg 1 times / day steady-state, topical dose: 0.25 mg route of administration: Topical experiment type: STEADY-STATE co-administered: |
ESTRADIOL plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
|
92 pg/mL |
0.05 mg 1 times / day multiple, topical dose: 0.05 mg route of administration: Topical experiment type: MULTIPLE co-administered: |
ESTRADIOL plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
236 pg × h/mL |
0.25 mg 1 times / day steady-state, topical dose: 0.25 mg route of administration: Topical experiment type: STEADY-STATE co-administered: |
ESTRADIOL plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10 h |
0.25 mg 1 times / day steady-state, topical dose: 0.25 mg route of administration: Topical experiment type: STEADY-STATE co-administered: |
ESTRADIOL plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
|
1.75 h |
0.05 mg 1 times / day multiple, topical dose: 0.05 mg route of administration: Topical experiment type: MULTIPLE co-administered: |
ESTRADIOL plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes | ||||
Page: - |
yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| minor | ||||
| minor | ||||
| minor | ||||
| minor | ||||
| minor | ||||
| minor | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| yes [Km 7 uM] | ||||
| yes | ||||
| yes | ||||
Page: - |
yes | |||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Estrogen and aryl hydrocarbon receptor expression and crosstalk in human Ishikawa endometrial cancer cells. | 2000 Apr |
|
| Involvement of cyclooxygenase 2 in the protective effect of 17beta-estradiol on hypercholesterolemic rabbit aorta. | 2000 Aug 28 |
|
| Indole-3-carbinol is a negative regulator of estrogen receptor-alpha signaling in human tumor cells. | 2000 Dec |
|
| Atheroprotective effect of estriol and estrone sulfate on human vascular smooth muscle cells. | 2000 Jan-Feb |
|
| Estradiol and pesticide methoxychlor do not exhibit additivity or synergism in the reproductive tract of adult ovariectomized mice. | 2000 Jul 28 |
|
| Crosstalk between estrogen receptor alpha and the aryl hydrocarbon receptor in breast cancer cells involves unidirectional activation of proteasomes. | 2000 Jul 28 |
|
| Six high-priority organochlorine pesticides, either singly or in combination, are nonestrogenic in transfected HeLa cells. | 2000 Mar-Apr |
|
| Estradiol acts as a germ cell survival factor in the human testis in vitro. | 2000 May |
|
| Assaying estrogenicity by quantitating the expression levels of endogenous estrogen-regulated genes. | 2000 May |
|
| Estrogen activation of the nuclear orphan receptor CAR (constitutive active receptor) in induction of the mouse Cyp2b10 gene. | 2000 Nov |
|
| Estradiol enhances the resistance of LDL to oxidation by stabilizing apoB-100 conformation. | 2000 Nov 14 |
|
| Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ERbeta. | 2000 Nov 17 |
|
| Changes in serum and tissue zinc levels in sex hormone-induced prostatic carcinogenesis in the noble rat. | 2000 Nov-Dec |
|
| Relative binding affinity does not predict biological response to xenoestrogens in rat endometrial adenocarcinoma cells. | 2000 Oct |
|
| Repression of chick multidrug resistance-associated protein 1 (chMRP1) gene expression by estrogen. | 2000 Oct 31 |
|
| NADPH- and hydroperoxide-supported 17beta-estradiol hydroxylation catalyzed by a variant form (432L, 453S) of human cytochrome P450 1B1. | 2000 Sep |
|
| Vitellogenin-induced pathology in male summer flounder (Paralichthys dentatus). | 2001 Feb |
|
| Use of salivary biomarkers in biobehavioral research: cotton-based sample collection methods can interfere with salivary immunoassay results. | 2001 Feb |
|
| Effects of follicle-stimulating hormone with and without luteinizing hormone on serum hormone concentrations, follicle growth, and intrafollicular estradiol and aromatase activity in gonadotropin-releasing hormone-immunized heifers. | 2001 Jan |
|
| Female steroid hormones modulate receptors for nerve growth factor in rat dorsal root ganglia. | 2001 Jan |
|
| Regulation and role of vascular endothelial growth factor in the corpus luteum during mid-pregnancy in rats. | 2001 Jan |
|
| Increased expression of a novel heat shock protein transcript in the mouse uterus during decidualization and in response to progesterone. | 2001 Jan |
|
| Regulation of progesterone receptors and decidualization in uterine stroma of the estrogen receptor-alpha knockout mouse. | 2001 Jan |
|
| Pregnancy stimulates secretion of adrenocorticotropin and nitric oxide from peripheral bovine lymphocytes. | 2001 Jan |
|
| Follicle selection in cattle: role of luteinizing hormone. | 2001 Jan |
|
| Lysyl oxidase and MMP-2 expression in dehydroepiandrosterone-induced polycystic ovary in rats. | 2001 Jan |
|
| Changes in follicle-stimulating hormone and follicle populations during the ovarian cycle of the common marmoset. | 2001 Jan |
|
| Estradiol-induced attenuation of pulmonary hypertension is not associated with altered eNOS expression. | 2001 Jan |
|
| Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride. | 2001 Jan |
|
| Metabolism of estradiol, ethynylestradiol, and moxestrol in rat uterus, vagina, and aorta: influence of sex steroid treatment. | 2001 Jan |
|
| Sex steroid hormones enhance immune function in male and female Siberian hamsters. | 2001 Jan |
|
| Rapid and reversible inhibition of brain aromatase activity. | 2001 Jan |
|
| Oestrogen-induced changes in the synaptology of the monkey (Cercopithecus aethiops) arcuate nucleus during gonadotropin feedback. | 2001 Jan |
|
| Stimulatory effect of clofibrate and gemfibrozil administration on the formation of fatty acid esters of estradiol by rat liver microsomes. | 2001 Jan |
|
| Influence of gender and sex hormones on nicotine acute pharmacological effects in mice. | 2001 Jan |
|
| Heat-shock factor-1, steroid hormones, and regulation of heat-shock protein expression in the heart. | 2001 Jan |
|
| Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. | 2001 Jan |
|
| Dose-response relationships and pharmacokinetics of vitellogenin in rainbow trout after intravascular administration of 17alpha-ethynylestradiol. | 2001 Jan |
|
| Evaluation of an EIA method for measuring serum levels of the estrogen metabolite 2-hydroxyestrone in adults. | 2001 Jan |
|
| Estradiol levels in psychotic disorders. | 2001 Jan |
|
| Neuroprotection by estradiol. | 2001 Jan |
|
| Effects of heterocyclic amines with mammary gland carcinogenic potential on estrogenic response of uterus in ovariectomized rats. | 2001 Jan 10 |
|
| Affinity labeling of rat glutathione S-transferase isozyme 1-1 by 17beta -iodoacetoxy-estradiol-3-sulfate. | 2001 Jan 19 |
|
| Reduction of gamma-aminobutyric acid-ergic neurotransmission as a putative mechanism of radiation induced activation of the gonadotropin releasing-hormone-pulse generator leading to precocious puberty in female rats. | 2001 Jan 5 |
|
| Hormone binding by protein disulfide isomerase, a high capacity hormone reservoir of the endoplasmic reticulum. | 2001 Jan 5 |
|
| Acquisition of Lubrol insolubility, a common step for growth hormone and prolactin in the secretory pathway of neuroendocrine cells. | 2001 Jan 5 |
|
| In vivo regulation of syndecan-3 expression in the rat uterus by 17 beta-estradiol. | 2001 Jan 5 |
|
| Glutathione stimulates sulfated estrogen transport by multidrug resistance protein 1. | 2001 Mar 2 |
|
| Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. | 2001 Mar 23 |
|
| Enhanced multispecificity of arabidopsis vacuolar multidrug resistance-associated protein-type ATP-binding cassette transporter, AtMRP2. | 2001 Mar 23 |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment:: Estradiol benzoate is not approved by the FDA for use in humans in the United States.
Start therapy with Climara (estradiol) 0.025 mg per day applied to the skin onceweekly. Transdermal system 0.025 mg per day, 0.0375 mg per day, 0.05 mg per
day, 0.06 mg per day, 0.075 mg per day and 0.1 mg per day
Route of Administration:
Transdermal
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:35:34 UTC 2021
by
admin
on
Fri Jun 25 21:35:34 UTC 2021
|
| Record UNII |
4TI98Z838E
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LOINC |
35384-7
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
34290-7
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
34286-5
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
12595-5
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
2239-2
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
WHO-ATC |
G03CA03
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
WHO-VATC |
QG03CA03
Created by
admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021
|
||
|
CFR |
21 CFR 522.840
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
83097-6
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
2240-0
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
14715-7
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
15062-3
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
12214-3
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
34288-1
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
FDA ORPHAN DRUG |
231706
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
WHO-VATC |
QG03CA53
Created by
admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021
|
||
|
LOINC |
25401-1
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
CFR |
21 CFR 310.527
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
WHO-VATC |
QG03AB08
Created by
admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021
|
||
|
NDF-RT |
N0000011402
Created by
admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021
|
||
|
WHO-ATC |
G03AA14
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
13883-4
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
2246-7
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
WHO-VATC |
QG03AA14
Created by
admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021
|
||
|
CFR |
21 CFR 556.240
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
72873-3
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
34287-3
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
55857-7
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
35207-0
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
21263-9
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LIVERTOX |
372
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
2243-4
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
2245-9
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
2238-4
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
31176-1
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
WHO-ATC |
G03CA53
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
WHO-ATC |
G03AB08
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
14960-9
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
2241-8
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
IOA (WITHDRAWN: CONTRACEPTION)
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
NDF-RT |
N0000000100
Created by
admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021
|
||
|
LOINC |
12213-5
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
34291-5
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
CFR |
21 CFR 522.2477
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
NDF-RT |
N0000175825
Created by
admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021
|
||
|
LOINC |
44730-0
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
34289-9
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
CFR |
21 CFR 862.1430
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
CFR |
21 CFR 862.1260
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
NCI_THESAURUS |
C2293
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
13736-4
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
55858-5
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
83096-8
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
2242-6
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
||
|
LOINC |
2244-2
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1013
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
PRIMARY | |||
|
200-023-8
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
PRIMARY | |||
|
ESTRADIOL
Created by
admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021
|
PRIMARY | |||
|
Estradiol
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
PRIMARY | |||
|
DB00783
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
PRIMARY | |||
|
SUB96040
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
PRIMARY | |||
|
M5028
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
PRIMARY | Merck Index | ||
|
D004958
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
PRIMARY | |||
|
50-28-2
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
PRIMARY | |||
|
406
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
PRIMARY | |||
|
C478
Created by
admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021
|
PRIMARY | |||
|
CHEMBL135
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
PRIMARY | |||
|
1057
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
PRIMARY | |||
|
50-28-2
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
PRIMARY | |||
|
SUB07242MIG
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
PRIMARY | |||
|
4TI98Z838E
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
PRIMARY | |||
|
4083
Created by
admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021
|
PRIMARY | RxNorm | ||
|
SUB21195
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
PRIMARY | |||
|
3589
Created by
admin on Fri Jun 25 21:35:35 UTC 2021 , Edited by admin on Fri Jun 25 21:35:35 UTC 2021
|
PRIMARY | |||
|
1250008
Created by
admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021
|
PRIMARY | USP-RS | ||
|
5757
Created by
admin on Fri Jun 25 21:35:36 UTC 2021 , Edited by admin on Fri Jun 25 21:35:36 UTC 2021
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
||
|
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
|
SUBSTANCE->BASIS OF STRENGTH | |||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> AGONIST |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE | |||
|
METABOLITE -> PARENT |
E2 is then extensively metabolized to estrone (E1) (15%), estrone sulfate (E1S) (65%), and other compounds.
|
||
|
METABOLITE -> PARENT | |||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
E2 is then extensively metabolized to estrone (E1) (15%), estrone sulfate (E1S) (65%), and other compounds.
|
||
|
METABOLITE LESS ACTIVE -> PARENT |
IN-VITRO
|
||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
PARENT -> METABOLITE ACTIVE | |||
|
PARENT -> METABOLITE |
Metabolite produced by hydrolysis. Estramustine,s primary mechanism of antineoplastic action is inhibition of mitosis.
PLASMA
|
||
|
METABOLITE -> PARENT |
IN-VITRO
Scientific Literature
|
||
|
METABOLITE -> PARENT |
MAJOR
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
IN-VIVO
URINE
|
||
|
PRODRUG -> METABOLITE ACTIVE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
USP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
PARENT -> IMPURITY | |||
|
IMPURITY -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Tmax | PHARMACOKINETIC |
|
ESTRADIOL VALERATE |
|
||
| Volume of Distribution | PHARMACOKINETIC |
|
|
|||
| Biological Half-life | PHARMACOKINETIC |
|
ESTRADIOL VALERATE |
|
||